BACKGROUND: Major depressive disorder (MDD) is the most common comorbid psychiatric condition associated with temporal lobe epilepsy (TLE). Preclinical and clinical studies suggest that 5-HT(1A) receptors play a role in the pathophysiology of both TLE and MDD. There is preliminary evidence for an association between decreased 5-HT(1A) receptor binding in limbic brain areas and affective symptoms in TLE patients. The objective of this study was to compare 5-HT(1A) receptor binding between TLE patients with and without MDD. For the first time, 5-HT(1A) receptor binding was measured in a sample large enough to permit sensitive comparisons between TLE patients with and without comorbid MDD diagnosed by clinical and structured psychiatric interviews. METHODS: Thirty-seven epilepsy patients with temporal lobe foci confirmed by ictal video-electroencephalogram (EEG) monitoring were recruited from the Clinical Epilepsy Section, National Institute of Neurological Disorders and Stroke. We performed interictal positron emission tomography scanning, with [(18)F]FCWAY, a fluorinated derivative of WAY100635, on a GE Medical Systems (Waukesha, Wisconsin) Advance scanner with continuous EEG monitoring. The 5-HT(1A) receptor binding was estimated by partial volume-corrected [(18)F]FCWAY V/f(1) values. RESULTS: In addition to decreased 5-HT(1A) receptor binding in the epileptic focus itself, comorbid MDD was associated with a significantly more pronounced reduction in 5-HT(1A) receptor binding in TLE patients, extending into non-lesional limbic brain areas outside the epileptic focus. Focus side and the presence of mesial temporal sclerosis were not associated with the presence of comorbid depression. CONCLUSIONS: Reductions in 5-HT(1A) receptor binding might help elucidate the neurobiological mechanisms underlying the TLE-MDD comorbidity.
BACKGROUND: Major depressive disorder (MDD) is the most common comorbid psychiatric condition associated with temporal lobe epilepsy (TLE). Preclinical and clinical studies suggest that 5-HT(1A) receptors play a role in the pathophysiology of both TLE and MDD. There is preliminary evidence for an association between decreased 5-HT(1A) receptor binding in limbic brain areas and affective symptoms in TLEpatients. The objective of this study was to compare 5-HT(1A) receptor binding between TLEpatients with and without MDD. For the first time, 5-HT(1A) receptor binding was measured in a sample large enough to permit sensitive comparisons between TLEpatients with and without comorbid MDD diagnosed by clinical and structured psychiatric interviews. METHODS: Thirty-seven epilepsypatients with temporal lobe foci confirmed by ictal video-electroencephalogram (EEG) monitoring were recruited from the Clinical Epilepsy Section, National Institute of Neurological Disorders and Stroke. We performed interictal positron emission tomography scanning, with [(18)F]FCWAY, a fluorinated derivative of WAY100635, on a GE Medical Systems (Waukesha, Wisconsin) Advance scanner with continuous EEG monitoring. The 5-HT(1A) receptor binding was estimated by partial volume-corrected [(18)F]FCWAY V/f(1) values. RESULTS: In addition to decreased 5-HT(1A) receptor binding in the epileptic focus itself, comorbid MDD was associated with a significantly more pronounced reduction in 5-HT(1A) receptor binding in TLEpatients, extending into non-lesional limbic brain areas outside the epileptic focus. Focus side and the presence of mesial temporal sclerosis were not associated with the presence of comorbid depression. CONCLUSIONS: Reductions in 5-HT(1A) receptor binding might help elucidate the neurobiological mechanisms underlying the TLE-MDD comorbidity.
Authors: Ramin V Parsey; Maria A Oquendo; R Todd Ogden; Doreen M Olvet; Norman Simpson; Yung-Yu Huang; Ronald L Van Heertum; Victoria Arango; J John Mann Journal: Biol Psychiatry Date: 2005-09-09 Impact factor: 13.382
Authors: Ales F Aliashkevich; Deniz Yilmazer-Hanke; Dirk Van Roost; Björn Mundhenk; Johannes Schramm; Ingmar Blümcke Journal: Acta Neuropathol Date: 2003-04-09 Impact factor: 17.088
Authors: W C Drevets; E Frank; J C Price; D J Kupfer; D Holt; P J Greer; Y Huang; C Gautier; C Mathis Journal: Biol Psychiatry Date: 1999-11-15 Impact factor: 13.382
Authors: R E Carson; L Lang; H Watabe; M G Der; H R Adams; E Jagoda; P Herscovitch; W C Eckelman Journal: Nucl Med Biol Date: 2000-07 Impact factor: 2.408
Authors: Andrey Finegersh; Christina Avedissian; Sadat Shamim; Irene Dustin; Paul M Thompson; William H Theodore Journal: Epilepsia Date: 2011-01-26 Impact factor: 5.864
Authors: Allison C Nugent; Ashley Martinez; Alana D'Alfonso; Carlos A Zarate; William H Theodore Journal: J Cereb Blood Flow Metab Date: 2015-03-31 Impact factor: 6.200